Product Description
Argatroban is a medication used to manage heparin-induced thrombocytopenia (HIT), which is a rare, life-threatening complication of heparin therapy. It is a direct thrombin inhibitor, a class of anticoagulant drugs. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK555971/)
Mechanisms of Action: DT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Austria | Canada | China | Denmark | Egypt | Finland | France | Germany | Greece | India | Italy | Japan | Korea | Malta | Netherlands | Norway | Romania | Saudi Arabia | Spain | Sweden | Switzerland | Turkey | United Kingdom | United States
Approved Indications: None
Company: Mitsubishi Tanabe
Company Location: Asia Pacific
Company Founding Year: 2007
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Czech Republic
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Heart Failure
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2025-524553-13-00 |
2025-524553-13-00 | P2 |
Not yet recruiting |
Heart Failure |
2028-02-29 |